Inactive Instrument

Analyst Reco. ESSA Pharma Inc. Toronto S.E.

Equities

Oppenheimer Adjusts ESSA Pharma's Price Target to $17 From $23, Maintains Outperform Rating	22-12-14	MT
Oppenheimer Adjusts ESSA Pharma Price Target to $23 From $22, Maintains Outperform Rating	22-06-28	MT
Piper Sandler Adjusts ESSA Pharma's Price Target to $20 From $50, Reiterates Overweight Rating	22-05-12	MT
ESSA PHARMA : Oppenheimer Adjusts ESSA Pharma PT to $22 From $36 on Delayed EPI-7386 Clinical Update, Maintains Outperform Rating	21-08-17	MT
ESSA PHARMA : Piper Sandler Starts ESSA Pharma at Overweight With $50 Price Target	21-03-04	MT
ESSA PHARMA : HC Wainwright Adjusts ESSA Pharma PT to $32 From $36, Maintains Buy Rating	21-02-25	MT
ESSA PHARMA : Oppenheimer Adjusts ESSA Pharma PT to $36 From $20, Maintains Outperform Rating	21-02-12	MT
ESSA PHARMA : HC Wainwright & Co. Adjusts Price Target on ESSA Pharma to $36 From $17, Maintains Buy Rating	21-02-11	MT
ESSA PHARMA : Oppenheimer Adjusts ESSA Pharma PT to $20 From $9, Maintains Outperform Rating	21-01-14	MT
ESSA PHARMA : Jefferies Starts ESSA Pharma at Buy With $17 Price Target	20-11-02	MT

No results for this search